What serious risk increases with the use of IV methylprednisolone?

The use of IV methylprednisolone, a corticosteroid, is associated with an increased risk of pulmonary infections. Corticosteroids can suppress the immune response, making patients more susceptible to infections, particularly in the lungs. This is especially important in patients who might already be at risk due to underlying conditions or other treatments that compromise their immune system.

In the context of corticosteroid therapy, patients may exhibit impaired cell-mediated immunity, which is crucial for fighting off infections. Consequently, the use of IV methylprednisolone can lead to a higher incidence of infections, including pneumonia and other pulmonary complications. Being mindful of this risk is critical in both prescribing and monitoring patients who receive this medication.